Showing results (91-100 of 114) with videos related to
Sort By:
Pageof 12
Clinical Lymphoma, Myeloma & Leukemia|April 18, 2026
Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin LymphomasMingyuan Sun, Keshu Zhou, Junyuan Qi, et al.BMC Cancer|July 12, 2022
Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer modelsDouglas D Fang, Ran Tao, Guangfeng Wang, et al.Cell & Bioscience|November 2, 2019
Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumorsXuechao Liu, Guangfeng Wang, Xianglei Yan, et al.Molecular Cancer Therapeutics|May 24, 2013
Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinomaMan-Si Wu, Guang-Feng Wang, Zhi-Qiang Zhao, et al.Journal of Medicinal Chemistry|April 2, 2004
Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligandsZhen-Dan Shi, Chang-Qing Wei, Kyeong Lee, et al.Journal for Immunotherapy of Cancer|July 13, 2026
BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for EGFR-mutated advanced non-small-cell lung cancer: a phase 1b trialYuxiang Ma, Chunjiao Wu, Yan-Qiu Zhao, et al.Journal of Medicinal Chemistry|March 25, 2017
Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical DevelopmentAngelo Aguilar, Jianfeng Lu, Liu Liu, et al.Journal of Medicinal Chemistry|March 30, 2011
A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatmentQian Cai, Haiying Sun, Yuefeng Peng, et al.Cell Reports. Medicine|September 20, 2025
A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancerSi Shi, Jian Zhang, Rujiao Liu, et al.Journal of Medicinal Chemistry|November 13, 2020
Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor RegressionJianyong Chen, Yunlong Zhou, Xuyuan Dong, et al.Pageof 12